2.84  0.19 (7.17%)		10-04 16:00
Open: 2.72 High: 2.8899 Volume: 118,076		Pre. Close: 2.65 Low: 2.64 Market Cap: 100(M)

Short term
Mid term
Targets	6-month :	3.84	1-year :	5.15
Resists	First :	3.29	Second :	4.4
Pivot price	3
Supports	First :	1.49	Second :	1.23
MAs	MA(5) :	2.83	MA(20) :	3.07
	MA(100) :	5.07	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	13.6	D(3) :	16
RSI	RSI(14): 49.6
52-week	High :	19.6	Low :	1.07

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ FBLG ] has closed above bottom band by 31.2%. Bollinger Bands are 75.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.9 - 2.92	2.92 - 2.93
Low:	2.6 - 2.62	2.62 - 2.64
Close:	2.8 - 2.84	2.84 - 2.88

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Thu, 03 Oct 2024
FBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024 - MSN

Wed, 21 Aug 2024
FibroBiologics (NASDAQ:FBLG) Stock Rises After Patent Application Announcement - News IMC

Mon, 12 Aug 2024
FibroBiologics CEO buys $16.2k in company stock - Investing.com

Mon, 12 Aug 2024
FibroBiologics executive buys $19,000 in company stock - Investing.com

Sun, 04 Feb 2024
StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs - Genetic Engineering & Biotechnology News

Wed, 31 Jan 2024
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	35 (M)
Shares Float	25 (M)
Held by Insiders	28.2 (%)
Held by Institutions	9.6 (%)
Shares Short	1,850 (K)
Shares Short P.Month	1,120 (K)

EPS	-0.61
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.08
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-61.6 %
Return on Equity (ttm)	-434.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.32
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	4 (M)

PE Ratio	-4.74
PEG Ratio	0
Price to Book value	-40.58
Price to Sales	0
Price to Cash Flow	-11.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.